文献速递临床试验与 GCP基础与转化研究

同种异体人脐带间充质干细胞治疗儿童重度支气管肺发育不良的随机对照试验方案

Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial).
PubMed 文献 · Trials · 2020-01-31

主要结局为累积氧疗时间,随访至24个月评估胸部影像学变化,旨在评估静脉输注同种异体hUC-MSCs的安全性和有效性。

要点

  • 全球首个评估静脉hUC-MSCs治疗儿童重度BPD的随机对照试验
  • 设低剂量与高剂量两个干预组,主要结局为累积氧疗时间
  • 随访1、3、6、12、24个月,关键随访指标为胸部影像学变化

核心结论

  • 静脉输注同种异体hUC-MSCs治疗儿童重度BPD的安全性和有效性尚待本试验验证。

研究设计与样本

  • 随机、单中心、开放标签、剂量递增的II期试验,计划纳入72例重度BPD患儿。

主要发现

  • 主要结局指标为累积氧疗时间。
  • 随访在干预后1、3、6、12、24个月进行,关键随访结局为胸部影像学变化。

关键数值与推荐

  • 对照组仅接受传统支持治疗,不给予hUC-MSCs。

临床怎么用

  • 若试验证实有效,静脉hUC-MSCs可能成为重度BPD患儿新的循证治疗选择。

局限性

  • 单中心、开放标签设计可能引入偏倚。
  • 样本量72例,剂量递增设计,结果需后续更大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchopulmonary dysplasia (BPD) is a complex lung pathological lesion secondary to multiple factors and one of the most common chronic lung diseases. It has a poor prognosis, especially in preterm infants. However, effective therapies for this disease are lacking. Stem-cell therapy is a promising way to improve lung injury and abnormal alveolarization, and the human umbilical cord (hUC) is a good source of mesenchymal stem cells (MSCs), which have demonstrated efficacy in other diseases. We hypothesized that intravenously administered allogeneic hUC-MSCs are safe and effective for severe BPD. METHODS: The MSC-BPD trial is a randomized, single-center, open-label, dose-escalation, phase-II trial designed to investigate the safety and efficacy of hUC-MSCs in children with severe BPD. In this study, 72 patients will be enrolled and randomly divided into two intervention groups and one control group. Patients in the intervention groups will receive a low dose of hUC-MSCs (n = 24; 2.5 million cells/kg) or a high dose of hUC-MSCs (n = 24; 5 million cells/kg) in combination with traditional supportive treatments for BPD. The patients in the control group (n = 24) will be treated with traditional supportive treatments alone without hUC-MSCs. The primary outcome measures will be cumulative duration of oxygen therapy. Follow-up assessments will be performed at 1, 3, 6, 12, and 24 months post intervention, and the key outcome during follow-up will be changes on chest radiography. Statistical analyses will evaluate the efficacy of the hUC-MSC treatment. DISCUSSION: This will be the first randomized controlled trial to evaluate the safety and efficacy of intravenously administered hUC-MSCs in children with severe BPD. Its results should provide a new evidence-based therapy for severe BPD. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03601416. Registered on 26 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu X, Xia Y, Zhou O, et al. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial). Trials. 2020. PMID: 32005282. doi:10.1186/s13063-019-3935-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。